(Q34237231)

31 July 2017

A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea (English)

1 reference

31 July 2017

0 references

randomized experiment

1 reference

inferred from title

irritable bowel syndrome

1 reference

Amanda Henry

7

0 references

Luca Marciani

object named as

Luca Marciani

5

0 references

Ian P. Hall

object named as

Ian Hall

8

0 references

Robin Spiller

object named as

Robin Spiller

10

0 references

author name string

Klara Garsed

1

1 reference

31 July 2017

Julia Chernova

2

1 reference

31 July 2017

Margaret Hastings

3

1 reference

31 July 2017

Ching Lam

4

1 reference

31 July 2017

Gulzar Singh

6

1 reference

31 July 2017

Peter Whorwell

9

1 reference

31 July 2017

language of work or name

English

0 references

publication date

12 December 2013

1 reference

31 July 2017

1 reference

31 July 2017

63

1 reference

31 July 2017

10

1 reference

31 July 2017

1617-1625

1 reference

Randomised clinical trial: alosetron improves quality of life and reduces restriction of daily activities in women with severe diarrhoea-predominant IBS.

31 July 2017

randomized experiment

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Postprandial changes in small bowel water content in healthy subjects and patients with irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Predictors of patient-assessed illness severity in irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

A randomized, double-blind, placebo-controlled study to assess efficacy and safety of 0.5 mg and 1 mg alosetron in women with severe diarrhea-predominant IBS.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Functional bowel disorders

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Incidence of ischemic colitis and serious complications of constipation among patients using alosetron: systematic review of clinical trials and post-marketing surveillance data

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Review article: serotonin receptors and transporters -- roles in normal and abnormal gastrointestinal motility

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Efficacy of alosetron in irritable bowel syndrome: a meta-analysis of randomized controlled trials

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Patient satisfaction with alosetron for the treatment of women with diarrhea-predominant irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Serotonin-transporter polymorphism pharmacogenetics in diarrhea-predominant irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Intestinal serotonin acts as a paracrine substance to mediate vagal signal transmission evoked by luminal factors in the rat

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Preclinical and clinical pharmacology of the 5-HT3 receptor antagonists

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

The 5-HT(3) receptor antagonist alosetron inhibits the colorectal distention induced depressor response and spinal c-fos expression in the anaesthetised rat.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Selective 5-hydroxytryptamine antagonism: a role in irritable bowel syndrome and functional dyspepsia?

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

GR 38032F (ondansetron), a selective 5HT3 receptor antagonist, slows colonic transit in healthy man.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Characterization of the alternating bowel habit subtype in patients with irritable bowel syndrome

28 July 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Clinical determinants of health-related quality of life in patients with irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

The PHQ-15: validity of a new measure for evaluating the severity of somatic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Postinfectious irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Serotonin signaling is altered in irritable bowel syndrome with diarrhea but not in functional dyspepsia in pediatric age patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Afferent hypersensitivity in a mouse model of post-inflammatory gut dysfunction: role of altered serotonin metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Ischemic colitis and complications of constipation associated with the use of alosetron under a risk management plan: clinical characteristics, outcomes, and incidences

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

The pharmacological properties of the novel selective 5-HT3 receptor antagonist, alosetron, and its effects on normal and perturbed small intestinal transit in the fasted rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

Evaluation of the pharmacological profile of ramosetron, a novel therapeutic agent for irritable bowel syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

An Irritable Bowel Syndrome-Specific Symptom Questionnaire: Development and Validation

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FGUTJNL-2013-305989

A 5HT3 antagonist corrects the postprandial colonic hypertonic response in carcinoid diarrhea.

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

An office guide to whole-gut transit time. Patients' recollection of their stool form.

28 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4173656

Simplified assessment of segmental colonic transit

28 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24334242

12 December 2020

inferred from PubMed ID database lookup

Development of the Perceived Stress Questionnaire: a new tool for psychosomatic research

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24334242

12 December 2020

inferred from PubMed ID database lookup

The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24334242

12 December 2020

inferred from PubMed ID database lookup

Identifiers

DOI

10.1136/GUTJNL-2013-305989

1 reference

31 July 2017

1 reference

31 July 2017

1 reference